Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation

BACKGROUND: The treatment of multiple myeloma (MM) has evolved significantly in the past decade, and new drug combinations have improved the response rates and prolonged survival. Studies comparing different induction chemotherapy regimens have shown that triple combinations have better results than...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Hematol Transfus Cell Ther
Main Authors: Crusoe, Edvan De Queiroz, Higashi, Fabiana, Martinez, Gracia, Bittencourt, Rosane, Pinto Neto, Jorge Vaz, Sousa, Lais, Santucci, Rodrigo, Magalhães, Roberto José Pessoa, Colli, Gilberto, Nunes, Renata Ferreira Marques, Ribeiro, Glaciano, Nicacio, Jandir, Zanella, Karla Richter, Kutner, Jose Mauro, Magalhaes, Andre, Leao, Danielle, Hallack Neto, Abrahão Elias, Braga, Walter, Souza, Emanuella G, Guimaraes, Antonio Julio A.M., Durigon, Giovanna Steffenello, Laks, Dani, Maiolino, Angelo, Hungria, Vania Tietsche de Moraes
Formato: Artigo
Idioma:Inglês
Publicado: Sociedade Brasileira de Hematologia e Hemoterapia 2020
Assuntos:
Original Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7248497/
https://ncbi.nlm.nih.gov/pubmed/31537476
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.htct.2019.05.004
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares